Replies to post #326324 on Bioelectronics Corp (BIEL)

[srinsocal]

Your BFF Jimmy got a 50% discount on his 600 million share conversion

<<<<<<<<<< the family gets their conversion price at 50% discount >>>>>>>>>>>

No one on this Board, except for you apparently, believes that there is currently a market for 20+ billion new shares of BIEL.

<<<<< How is that good for the stockholders for when they do 'unload' their substantial amount of shares >>>>>

The only way KW, PW, and RS get their loans repaid is if BIEL becomes successful.

Since BIEL pays most of its debts in shares, a solvent BIEL trading at .002 lowers the convertible debt by a factor of 10, if it was 20 billion shares at a .0002 SP it is 2 billion shares at a .002 SP .

A successful BIEL trading at .02 lowers the convertible debt by a factor of 100, if it was 20 billion shares at a .0002 SP it is 200 million shares at a .02 SP .

[GetSeriousOK]

The main problem here is not the pile of convertible debt held by the insiders. It's the lack of sales.

This is still a developmental biotech, not a blue chipper trading on NASDAQ. That means any course of action has to benefit the company first and shareholders second. "How is that good for the stockholders" doesn't apply here.

I'm sure that Whelan and Staelin and the other Whelans will convert and dump after the R/S we all know is coming, but that won't bring any new money into the company. They need funding and they need a new business plan. The primary reason for doing a R/S won't be to enrich the insiders -- it will be to fund the company so they can change course and implement a new business plan.

That's the optimistic viewpoint. I'm not going to express the negative viewpoint. We all know what THAT is.

Can this company pull it off? Possibly, but unlikely, because IMO management is ignorant, inexperienced, and lacking in vision and ambition. They don't HAVE a new business plan, IMO, and they're unlikely to find one.

Prove me wrong, Whelan.